Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes. - 2Change Your Skincare: 10 Inventive Magnificence Gadgets
- 3As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- 4The most effective method to Go Down Abundance through Ages with Disc Rates
- 5What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- New hybrid mpox strain discovered in UK after US reports local spread
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- The Most Important Crossroads in Olympic History
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
